ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02535078
Recruitment Status : Recruiting
First Posted : August 28, 2015
Last Update Posted : July 25, 2018
Sponsor:
Collaborator:
MedImmune LLC
Information provided by (Responsible Party):
Immunocore Ltd

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 2018
  Estimated Study Completion Date : November 2019